期刊文献+

High-risk endometrial cancer may be benefit from adjuvant radiotherapy plus chemotherapy 被引量:4

High-risk endometrial cancer may be benefit from adjuvant radiotherapy plus chemotherapy
下载PDF
导出
摘要 Objective: To present patterns of practice and outcomes in the adjuvant treatment of intermediate- and high-risk endometrial cancer. Methods: Retrospective data on 224 women with intermediate-risk and high-risk endometrial cancer from 1999 to 2006 were reviewed. All patients underwent surgical staging. Patterns of adjuvant treatment, consisting of pelvic radiotherapy, chemotherapy, and radiotherapy plus chemotherapy, were assessed. The 3- and 5-year disease-specific survival (DSS) rates were calculated using the Kaplan-Meier method. Results: The difference in 5-year DSS rate was statistically significant between adjuvant group and non-adjuvant group (80.65% vs. 63.80%, P=0.040). In 110 high-risk patients who underwent adjuvant treatment, both 5-year DSS rate and recurrent rate were significantly different in combined radiotherapy and chemotherapy group compared with radiotherapy alone and chemotherapy alone groups (DSS rate, P=0.049; recurrent rate, P=0.047). In 83 intermediate-risk women who underwent adjuvant treatment, there was no significant difference in 5-year DSS rate and recurrence rate among the combined radiotherapy and chemotherapy, radiotherapy alone and chemotherapy alone groups (DSS rate, P=0.776; recurrent rate, P=0.937). Objective: To present patterns of practice and outcomes in the adjuvant treatment of intermediate- and high-risk endometrial cancer. Methods: Retrospective data on 224 women with intermediate-risk and high-risk endometrial cancer from 1999 to 2006 were reviewed. All patients underwent surgical staging. Patterns of adjuvant treatment, consisting of pelvic radiotherapy, chemotherapy, and radiotherapy plus chemotherapy, were assessed. The 3- and 5-year disease-specific survival (DSS) rates were calculated using the Kaplan-Meier method. Results: The difference in 5-year DSS rate was statistically significant between adjuvant group and non-adjuvant group (80.65% vs. 63.80%, P=0.040). In 110 high-risk patients who underwent adjuvant treatment, both 5-year DSS rate and recurrent rate were significantly different in combined radiotherapy and chemotherapy group compared with radiotherapy alone and chemotherapy alone groups (DSS rate, P=0.049; recurrent rate, P=0.047). In 83 intermediate-risk women who underwent adjuvant treatment, there was no significant difference in 5-year DSS rate and recurrence rate among the combined radiotherapy and chemotherapy, radiotherapy alone and chemotherapy alone groups (DSS rate, P=0.776; recurrent rate, P=0.937).
出处 《Chinese Journal of Cancer Research》 SCIE CAS CSCD 2012年第4期332-339,共8页 中国癌症研究(英文版)
基金 supported by Funds of Capital Medical Development Foundation (2007-1049)
关键词 Adjuvant treatment CHEMOTHERAPY endometrial cancer RADIOTHERAPY RECURRENCE Adjuvant treatment chemotherapy endometrial cancer radiotherapy recurrence
  • 引文网络
  • 相关文献

参考文献3

二级参考文献32

  • 1王志启,王建六,赵丹,高敏,魏丽惠.晚期子宫内膜癌患者预后及其相关因素分析[J].实用妇产科杂志,2007,23(1):39-42. 被引量:7
  • 2Creasman WT, Odicino F, Maisonneuve P,et al. Carcinoma of the corpus uteri. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet, 2006,95 : 105- 143.
  • 3Smith RS, Kapp DS, Chen Q, et al. Treatment of high-risk uterine cancer with whole abdominopelvic radiation therapy. Int J Radiat Oncol Biol Phys ,2000 ,48:767-778.
  • 4Randall ME, Filiaci VL, Muss H, et al. Randomized phase Ⅲ trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol,2006,24:36-44.
  • 5Schorge JO, Molpus KL, Goodman A, et al. The effect of postsurgical therapy on stage Ⅲ endometrial carcinoma. Gynecol Oncol, 1996,63 : 34 -39.
  • 6Aoki Y, Kase H, Watanabe M, et al. Stage Ⅲ endometrial cancer: analysis of prognostic factors and failure patterns after adjuvant chemotherapy. Gynecol Oncol,2001,83 : 1-5.
  • 7Goff BA, Goodman A, Muntz HG, et al. Surgical stage Ⅳ endometrial carcinoma: a study of 47 cases. Gynecol Oncol,1994, 52:237-240.
  • 8Bristow RE, Zerbe MJ, Rosenshein NB, et al. Stage IVB endometrial carcinoma: the role of cytoreductive surgery and determinants of survival. Gynecol Oncol,2000 ,78 :85-91.
  • 9Mikuta JJ. International Federation of Gynecology and Obstetrics staging of endometrial cancer 1988. Cancer,1993,71:1460-1463.
  • 10Lambrou NC, Gomez-Marin O, Mirhashemi R, et al. Optimal surgical cytoreduction in patients with Stage Ⅲ and Stage Ⅳ endometrial carcinoma: a study of morbidity and survival. Gynecol Oncol,2004,93:653-658.

共引文献30

同被引文献19

引证文献4

二级引证文献44

;
使用帮助 返回顶部